RT Journal Article
T1 The economic burden of metastatic breast cancer in Spain.
A1 Bermejo de Las Heras, Begoña
A1 Cortes Ramon Y Cajal, Javier
A1 Galve Calvo, Elena
A1 de la Haba Rodriguez, Juan
A1 Garcia Mata, Jesus
A1 Moreno Anton, Fernando
A1 Pelaez Fernandez, Ignacio
A1 Rodriguez-Lescure, Alvaro
A1 Rodriguez Sanchez, Cesar A
A1 Ruiz-Borrego, Manuel
A1 Remak, Edit
A1 Barra, Magdolna
A1 Rivero, Maria
A1 Soto Alvarez, Javier
K1 Costs of illness
K1 Direct costs
K1 Metastatic breast cancer
K1 Resource utilisation
K1 Treatment patterns
AB The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years. An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over 5 years or death. Resource use data were collected through a physician survey conducted with 10 clinical experts in Spain. The model distinguished patients according to HER2 and hormonal receptor (HR) status, and followed the patient cohort in monthly cycles. The incident cohort was estimated to be 2,923 patients with mBC, consisting of 1,575 HER2-/HR+, 520 HER2+/HR+, 324 HER2+/HR-, and 503 triple negative patients. The estimated mean survival over the 5-year time period was 2.51 years, on average, with longer survival of 3.36 years for HER2+/HR+, 2.41 years for HER2-/HR+, 2.82 years for HER2+/HR- and shortest mean survival of 1.74 years for triple negative patients. The total costs were €469,92,731 for the overall population, €190,079,787 for the HER2-/HR+, €151,045,260 for the HER2+/HR+, €80,827,171 for the HER2+/HR- and €47,540,512 for the triple negative subgroups over 5 years. Per patient total costs were €160,642 on average, €120,664 for HER2-/HR+, €290,346 for HER2+/HR+, €249,152 for HER2+/HR-and €94,572 for triple negative patients over 5 years. The economic burden of mBC in Spain is significant, but differs by HER2 and HR status. HER2-/HR +patients account for the highest burden due to the prevalence of this category, but HER2+/HR +patients have the highest per patient costs.
PB BMJ Group
SN 2047-9956
YR 2018
FD 2018-06-26
LK http://hdl.handle.net/10668/15115
UL http://hdl.handle.net/10668/15115
LA en
NO Bermejo de Las Heras B, Cortes Ramon Y Cajal J, Galve Calvo E, de la Haba Rodriguez J, Garcia Mata J, Moreno Anton F, et al. The economic burden of metastatic breast cancer in Spain. Eur J Hosp Pharm. 2020 Jan;27(1):19-24
DS RISalud
RD Apr 11, 2025